The University of Miami has been awarded a $257,429 Project Grant from the National Institutes of Health's Research Infrastructure Programs (CFDA 93.351) to develop strategies for preventing or eliminating host immune responses towards adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (bNAbs) against HIV infection.
The key products or services to be delivered under this two-year grant include: 1) Attempting to induce tolerance towards AAV-delivered antibodies through a synergistic drug treatment regimen of rapamycin and ibrutinib in rhesus monkeys, and 2) Exploring the use of nucleoside-modified mRNA delivery to prevent de novo immune responses against AAV-delivered bNAbs and potentially revert anti-drug antibodies. The results from these experiments will define the conditions that can consistently achieve tolerance to AAV-delivered anti-HIV antibodies, with the ultimate goal of enabling long-term delivery of potent bNAbs for HIV prevention and treatment.
Generated 3/4/25, 7:44 AM